Nathan Carberry
YOU?
Author Swipe
View article: Thalamic volume as a susceptibility/risk biomarker for C9orf72 phenoconversion
Thalamic volume as a susceptibility/risk biomarker for C9orf72 phenoconversion Open
Background C9orf72 repeat expansions are the most frequent genetic risk factor of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD). With growing interest in the prospect of preventing clinically manifest disease, t…
View article: Surgical Treatment of Radiation-Induced Brachial Plexus Neuropathy in Breast Cancer Patients after Adjuvant Radiotherapy: A Systematic Review
Surgical Treatment of Radiation-Induced Brachial Plexus Neuropathy in Breast Cancer Patients after Adjuvant Radiotherapy: A Systematic Review Open
Purpose Radiotherapy is a frequently employed adjuvant treatment modality in breast cancer patients that carries debilitating side effects including radiation-induced brachial plexus neuritis (RIBPN). RIBPN is a neurological impairment tha…
View article: Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral Sclerosis
Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral Sclerosis Open
MMI is a recognizable syndrome. Although nonspecific, it identifies presymptomatic carriers at elevated risk of ALS phenoconversion. Combining MMI with emerging biomarkers of underlying pathology may help differentiate those who are prodro…
View article: Pridopidine in Amyotrophic Lateral Sclerosis
Pridopidine in Amyotrophic Lateral Sclerosis Open
Importance Amyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention. Objective To determine the effects of pridopidine, a σ1-receptor agonist, in ALS. Design, Settings, and Part…
View article: Verdiperstat in Amyotrophic Lateral Sclerosis
Verdiperstat in Amyotrophic Lateral Sclerosis Open
Importance Myeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via reduced ne…
View article: CNM-Au8 in Amyotrophic Lateral Sclerosis
CNM-Au8 in Amyotrophic Lateral Sclerosis Open
Importance Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of gold nanocrystals that catalyzes the conversion of nicotinamide adenine dinucleotide hydride into NAD + , resu…
View article: Publisher Correction: The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology
Publisher Correction: The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology Open
View article: Intermuscular coherence as an early biomarker for amyotrophic lateral sclerosis: The protocol for a prospective, multicenter study
Intermuscular coherence as an early biomarker for amyotrophic lateral sclerosis: The protocol for a prospective, multicenter study Open
Objective To describe the protocol of a prospective study to test the validity of intermuscular coherence (IMC) as a diagnostic tool and biomarker of upper motor neuron degeneration in amyotrophic lateral sclerosis (ALS). Methods This is a…
View article: The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology Open
View article: Amyotrophic lateral sclerosis care and research in the United States during the <scp>COVID</scp>‐19 pandemic: Challenges and opportunities
Amyotrophic lateral sclerosis care and research in the United States during the <span>COVID</span>‐19 pandemic: Challenges and opportunities Open
Coronavirus disease 2019 has created unprecedented challenges for amyotrophic lateral sclerosis (ALS) clinical care and research in the United States. Traditional evaluations for making an ALS diagnosis, measuring progression, and planning…